Free Interferon-α/β Receptors in the Circulation of Patients with Adenocarcinoma

Cancer

Volumn 98, Issue 12, 2003, Pages 2730-2733

  Ambrus Sr , Julian L ^a   Dembinski, Wlodzimierz ^a   Ambrus Jr , Julian L ^a   Sykes, Donald E ^a   Akhter, Selina ^a   Kulaylat, Mahmoud N ^a   Islam, Abul ^a   Chadha, Kailash C ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Adenocarcinoma; Interferon receptors; Patients; Therapy

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BETA INTERFERON; BETA INTERFERON RECEPTOR; INTERFERON RECEPTOR; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ASTROCYTOMA; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER GROWTH; CANCER PATIENT; CANCER SUSCEPTIBILITY; COLON CARCINOMA; CONTROLLED STUDY; DISSEMINATED CANCER; FEMALE; HODGKIN DISEASE; HUMAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; TRANSITIONAL CELL CARCINOMA; UTERUS CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON TYPE I; INTERFERON-ALPHA; INTERFERON-BETA; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; NEOPLASMS; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON;

EID: 0345098447     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11843     Document Type: Article

References (25)

1. Gutterman J. Cytokine therapeutics: lessons from interfer-on-α. Proc Natl Acad Sci USA. 1996;91:1198-1205.
2. Pitha PM. Introduction of interferon's connection to cancer. Semin Cancer Biol. 2000;10:69-72.
3. Einhorn S, Grander D. Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res. 1996;16:275-281.
4. Einhorn S, Strander H. Interferon treatment of human malignancies: a short review. Med Oncol Tumor Pharmacother. 1993;10:25-29.
5. Ambrus JL, Ambrus JL Jr., Chadha S, et al. Mechanism(s) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis. Res Commun Mol Pathol Pharmacol. 1997;96:255-265.
6. Ambrus JL, Poiesz BJ, Lillie MA, Stadler S, DiBernardino L, Chadha KC. Interferon and interferon inhibitor levels in patients infected with varicella-zoster virus, AIDS, ARC, Kaposi's sarcoma and normal individuals. Am J Med. 1989;87:405-407.
7. Ikossi-O'Connor MG, Ambrus JL, West T, Lillie MA, Milgrom H, Chadha KC. Interferon and interferon inactivators in patients with acquired immune deficiency syndrome and Kaposi's sarcoma. Res Commun Chem Pathol Pharmacol. 1984;45:271-277.
8. O'Connor MGI, Chadha KC, Lillie MA, et al. Interferon inactivator(s) in patients with AIDS and AIDS-related Kaposi's sarcoma. Am J Med. 1986;81:783-786.
9. Chadha KC, Ambrus JL, Ikossi MG. Interferons and interferon inactivators in AIDS, ARC, and in cancer patients. In: Cantell K, Schellekens H, editors. The biology of the interferon system. Boston: Martinue Nijhoff Publishers, 1987:423-427.
10. Ambrus JL, Chadha KC, Ambrus JL Jr. Interferon inhibitors in Wegner's granulomatosis. Ann Intern Med. 1991;114:606-607.
11. Chadha KC, Ambrus JL, Stadler S, Ambrus JL Jr. Interferon inhibitor in the blood of patients with systemic lupus erythematosus. J Biol Reg Homeostatic Agents. 1991;5:1-9.
12. Chadha KC, Ambrus JL, Halpern J, Khalil M, Piver MS, Hreshchyshyn MM. The interferon system in gynecologic cancer: effect of radiation and chemotherapy. Cancer. 1991;67:87-91.
13. O'Connor MGI, Ambrus JL, Chadha KC. Regulation of in vitro human leukocyte interferon production: effect of prostaglandin synthetase and phosphodiesterase inhibition. Res Commun Chem Pathol Pharmacol. 1986;54:379-384.
14. Cesario T, Vaziri N, Tilles J. Inactivators of fibroblast interferon found in human serum. Infect Immun. 1979;24:851-855.
15. Havredaki M, Barona F. Variations of interferon inactivators and/or inhibitors in human serum and their relationship to interferon therapy. Jpn J Med Sci Biol. 1985;38:107-111.
16. Karmaniolas KD, Papalampros TS, Papavassiliou ED, Liatis S, Kalantzis N. Detection of interferon inhibitors or antagonists in gastrointestinal malignancies. Hepatogastronenterology. 1998;45:2244-2247.
17. Lefkowitz EJ, Fleischmann WR Jr. An inhibitor of interferon action: II biological properties of the IFN-gamma associated inhibitor of interferon action. J Interferon Res. 1985;5:101-110.
18. Tsantakis G, Schizas N, Harvedaki M. Interferon inhibitors and/or inactivators in sera from patients with neoplasias. Arch Immunol Ther Exp (Warsz). 1993;41:335-337.
19. Stefanovich V, Ambrus JL, Ambrus CM, Karakousis C, Takita H. Cyclic nucleotide phosphodiesterases in normal and malignant human tissues. J Med. 1981;12:243-250.
20. Novick D, Cohen B, Rubinstein M. Soluble interferon-alpha receptor molecules are present in body fluids. FEBS Lett. 1992;314:445-448.
21. Novick D, Engelmann H, Wallach D, Leitner O, Rubinstein O. Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J Chromatogr. 1990;510:331-337.
22. Novick D, Engelmann H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989;170:1409-1414.
23. Hardy MP, Owczarek CM, Trajanovska S, Liu X, Kola I, Hertzog PJ. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood. 2001;97:473-482.
24. Spriggs MK. Poxvirus-encoded soluble cytokine receptors. Virus Res. 1994;33:1-10.
25. Basler CF, Wang X, Muhlberger E, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci. 2000;97:12289-12294.